Anti-emetics 2005: an overview and the MASCC guidelines applied in practice

Hesketh, 2003, J Clin Oncol, 2, 4112, 10.1200/JCO.2003.01.095 Poli-Bigelli, 2003, Addition of the neurokinin 1 receptor antagonist aprepitant to standard anti-emetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America, Cancer, 97, 3090, 10.1002/cncr.11433 Warr, 2005, Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy, J Clin Oncol, 23, 2822, 10.1200/JCO.2005.09.050 1998, 9, 811 Gralla, 1999, Recommendations for the use of anti-emetics: evidence-based clinical practice guidelines, J Clin Oncol, 17, 2971, 10.1200/JCO.1999.17.9.2971 Eisenberg, 2003, Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist, Cancer, 98, 2473, 10.1002/cncr.11817 Gralla, 2003, Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron, Ann Oncol, 14, 1570, 10.1093/annonc/mdg417 Aapro, 2003, Palonosetron is effective in preventing acute and delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, Support Care Cancer, 11, 391 ESMO Guidelines Task Force, 2001, ESMO recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV), Ann Oncol, 12, 1059, 10.1023/A:1017413507554 Grunberg, 2005, Evaluation of new anti-emetic agents and definition of antineoplastic agent emetogenicity — an update, Supp Care Cancer, 13, 80, 10.1007/s00520-004-0718-y Kris, 2005, Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy, Supp Care Cancer, 13, 85, 10.1007/s00520-004-0699-x Herrstedt, 2005, Acute emesis: moderately emetogenic chemotherapy, Supp Care Cancer, 13, 97, 10.1007/s00520-004-0701-7 Roila, 2005, Delayed emesis: moderately emetogenic chemotherapy, Supp Care Cancer, 13, 104, 10.1007/s00520-004-0700-8 Dranitsaris, 2001, Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study, Supp Care Cancer, 9, 611, 10.1007/s005200100273 Nolte, 1998, Assuring the optimal use of serotonin antagonist antiemetics: the process for the development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center, J Clin Oncol, 16, 771, 10.1200/JCO.1998.16.2.771